Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130278 | 0.97 | SIGMAR1 (0.58) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL133038 | 0.97 | SIGMAR1 (0.58) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL130390 | 0.92 | SIGMAR1 (0.54) | MAOAMAOBSIGMAR1L3MBTL1HTR2A | |
| SCHEMBL451456 | 0.86 | MAOA (0.74) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL7036785 | 0.85 | TDP1 (0.53) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL676854 | 0.83 | SIGMAR1 (0.71) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL8095284 | 0.83 | SIGMAR1 (0.71) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL8085946 | 0.83 | SIGMAR1 (0.71) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL8094527 | 0.83 | SIGMAR1 (0.71) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL6443055 | 0.83 | MAOA (0.70) | MAOAMAOBSIGMAR1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| CN-117813313-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4314014-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-1192178-A2 | RUFOMYCINS AND DERIVATIVES THEREOF USEFUL AS INHIBITORS OF MULTI-DRUG RESISTANCE ASSOCIATED PROTEIN-1 (MRP-1) | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000078795-A2 | RUFOMYCINS AND DERIVATIVES THEREOF USEFUL AS INHIBITORS OF MULTI-DRUG RESISTANCE ASSOCIATED PROTEIN-1 (MRP-1) | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | claimed |
| US-5559134-A | Leukotriene-B4 antagonists, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-24 | — | — | US | claimed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| CN-117813313-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4314014-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11576914-B2 | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof | THE DOSHISHA (JP) | 2023-02-14 | — | — | US | disclosed |
| CN-109476841-B | Novel polymer derivative and novel polymer derivative imaging probe using same | 日本化药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| EP-0186977-A2 | Renin-inhibitory dipeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-07-09 | — | — | EP | disclosed |
| US-4518596-A | Antithrombotic use of 2-(perhydro-1,4-diazino)-pyrimido (5,4,D)-pyrimidines | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | disclosed |
| EP-0055444-B1 | TRISUBSTITUTED PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0023559-B1 | 2-(PERHYDRO-1,4-DIAZINO)-PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-09-19 | — | — | EP | disclosed |
| EP-0055444-A2 | Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1982-07-07 | — | — | EP | disclosed |
| EP-0023559-A1 | 2-(Perhydro-1,4-diazino)-pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576914-B2 | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof | TGFBR1, FIBP, TGFB1 | MAOA 2716/4885MAOB 2578/4885SIGMAR1 4492/4885 |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | MAOA 4162/4885MAOB 4367/4885SIGMAR1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.